Home > Companies > Focus Laboratories Inc

Focus Laboratories Inc

focuslaboratories.com

FOCUS Laboratories is a specialty eye care pharmaceutical company that is dedicated to providing innovative, high quality medications and treatments to eye care providers that will improve the quality of the life of their patients. While our goal is to provide the most effective and innovative medications to patients and health care providers every day, we also strive to provide these treatments at a cost that will fit into most family budgets.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

National Medtech & Biotech Summit 2024

Conference

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference

Related News

Pharma Tech

XTALPI ANNOUNCES COLLABORATION WITH LILLY, USING AI + ROBOTICS TO UNCOVER FIRST-IN-CLASS THERAPEUTICS

PRNewswire | May 31, 2023

Today, XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, announced an AI drug discovery collaboration of up to $250 million in upfront and milestone payments with Eli Lilly and Company. The collaboration will leverage XtalPi's integrated AI capabilities and robotics platform to de novo design and deliver drug candidates for an undisclosed target. XtalPi has established itself as an industry leader in combining...

Business Insights, PHARMACY MARKET

OM1 UNVEILS PATENTED, AI-POWERED PLATFORM TO ACCELERATE PERSONALIZED MEDICINE

businesswire | April 17, 2023

OM1, a leading real-world data, outcomes and technology company with a focus on chronic conditions, today launched PhenOM™, its artificial intelligence-powered platform for personalized medicine. Calibrated using OM1’s longitudinal health history datasets, PhenOM uses AI to identify unique digital phenotypes associated with conditions and outcomes and compare patients’ records to them to highlight risks and opportunities. PhenOM powers personalized healthcare insights at ...

Business Insights

ZENAS BIOPHARMA ACQUIRES EXCLUSIVE WORLDWIDE RIGHTS TO OBEXELIMAB FROM XENCOR

Xencor, Zenas BioPharma | November 22, 2021

Xencor, Inc. a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas BioPharma (“Zenas”), a global biopharmaceutical company based in the USA and China committed to the development and delivery of immune-based therapies, today announced that Zenas has acquired from Xencor exclusive worldwide rights to develop, manufacture and commercialize the investigational antibody obexelima...

Pharma Tech

AERORX PARTNERS WITH HCMED TO DEVELOP A NEBULIZED LABA/LAMA COMBINATION SOLUTION FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

AeroRx Partners | October 03, 2022

AeroRx Therapeutics, LLC. and HCmed Innovations Co., Ltd. have initiated a collaboration, introducing a LABA/LAMA combination solution for delivery with a breath-actuated nebulizer. This collaboration sets forth the framework by which both companies will work together to develop a new nebulized combination formulation for the treatment of chronic obstructive pulmonary disease. According to market reports, it is estimated that there would be close to 34.5 million COPD patients worl...

Pharma Tech